Genmab Revenue

In the year 2024, Genmab had annual revenue of 21.53B DKK with 30.67% growth. Genmab had revenue of 6.44B in the quarter ending December 31, 2024, with 35.34% growth.

Revenue

21.53B

Revenue Growth

+30.67%

P/S Ratio

3.88

Revenue / Employee

8.03M

Employees

2,682

Market Cap

83.50B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	21.53B	5.05B	30.67%
Dec 31, 2023	16.47B	1.97B	13.57%
Dec 31, 2022	14.51B	6.09B	72.33%
Dec 31, 2021	8.42B	-1.69B	-16.75%
Dec 31, 2020	10.11B	4.75B	88.43%
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Novo Nordisk	290.40B
Coloplast	27.45B
Demant	22.42B
ALK-Abelló	5.54B
Ambu A/S	5.65B
Zealand Pharma	62.69M
H. Lundbeck	22.00B
GN Store Nord	17.99B

Revenue Rankings

Genmab News

2 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
9 days ago - Genmab's Outlook Beyond Darzalex's Patent Cliff - Seeking Alpha
9 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 - GlobeNewsWire
10 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
14 days ago - Genmab A/S Share Capital Reduction - GlobeNewsWire
17 days ago - Transactions In Connection with Share Buy-back Program - GlobeNewsWire
23 days ago - Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons - GlobeNewsWire
23 days ago - Genmab drops as Bernstein cuts on Darzalex patent cliff - Seeking Alpha

More News